+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model



Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model



Antimicrobial Agents and ChemoTherapy 39(9): 2155-2157



In the dexamethasone-treated rat model of cryptosporidiosis, paromomycin was effective at a dosage of 50 mg/kg/day or more for ileal infection and 200 mg/kg/day or more for cecal infection. At 1 and 3 weeks after treatment, a persistent infection was demonstrated in all rats. These results confirm the anticryptosporidial activity of paromomycin and underscore the limitations of this compound because of its potential toxicity at such high dosages and its inability to eradicate the infection.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 002833967

Download citation: RISBibTeXText

PMID: 8540737

DOI: 10.1128/aac.39.9.2155


Related references

Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model. Antimicrobial Agents and ChemoTherapy 38(7): 1681-1682, 1994

Absence of systemic absorption of oral paromomycin during long-term, high-dose treatment for cryptosporidiosis in AIDS. Journal of Infectious Diseases 170(3): 749-750, 1994

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood 111(2): 968-969, 2008

Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clinical and Diagnostic Laboratory Immunology 1(4): 450-463, 1994

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Annals of Oncology 17(6): 1000-1006, 2006

Evaluation of a combination antiemetic regimen including iv high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens. Cancer Treatment Reports 69(7-8): 909-910, 1985

Evaluation of a combination antiemetic regimen including intravenous high dose metoclopramide dexamethasone and diphenhydramine in cisplatin based chemotherapy regimens. Cancer Treatment Reports 8: 909-910, 1985

Randomized Trial for the Control of Acute Vomiting in Cisplatin-Treated Patients: High-Dose Metoclopramide with Dexamethasone and Lorazepam as Adjuncts versus High-Dose Alizapride plus Dexamethasone and Lorazepam. Oncology 48(5): 397-402, 2009

Randomized trial for the control of acute vomiting in cisplatin-treated patients: high-dose metoclopramide with dexamethasone and lorazepam as adjuncts versus high-dose alizapride plus dexamethasone and lorazepam. Study of the incidence of delayed emesis. Oncology 48(5): 397-402, 1991

Cryptosporidiosis in a renal transplant patient treated with paromomycin. Annals of Saudi Medicine 27(5): 373-374, 2007

Serum paromomycin levels in AIDS patients treated for cryptosporidiosis. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS Author Eleventh International Conference on AIDS, Vol One One world: One hope : 320-321, 1996

Evaluation for the development of 11q23 rearrangements in lymphoma patients treated with a high dose VP-16 and cyclophosphamide salvage regimen. Leukemia and Lymphoma 44(6): 1001-1009, 2003

High-dose dexamethasone and high-dose metoclopramide versus high-dose dexamethasone and sulpiride in the management of cisplatin-induced emesis. Oncology 45(4): 297-299, 1988

Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone. Cancer ChemoTherapy and Pharmacology 17(1): 75-79, 1986

A modified high-dose dexamethasone regimen for primary systemic amyloidosis. Blood 94(10 Suppl. 1 Part 1): 317a, 1999